Abemaciclib for Bone and Soft Tissue Sarcoma With Cyclin-Dependent Kinase (CDK) Pathway Alteration
Status:
Recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, phase II study that will enroll a total of 45 subjects. All subjects
will have a confirmed diagnosis of metastatic or unresectable soft tissue sarcoma or bone
sarcoma. All subjects must have intact Rb, identified at the time of screening, by
immunohistochemistry testing of submitted tumor specimen. Subjects will receive Abemaciclib
200 mg twice daily until progression or discontinuation criteria are met.